iktos Email Formats

Biotechnology Research • Paris, Île-de-France, France • 51-100 Employees

iktos Email Formats

iktos uses 5 email formats. The most common is {first initial}.{last name} (e.g., j.doe@iktos.ai), used 50% of the time.

Format	Example	Percentage
{first initial}.{last name}	j.doe@iktos.ai	56.8%
{first name}.{last name}	john.doe@iktos.ai	38.6%
{first initial}.{second initial}{last name}	j.odoe@iktos.ai	2.3%

Key Contacts at iktos

Hideyoshi Fuji

Representative Director At Iktos K.K./Vp, Japan Business Development And Operations

Quentin Perron

Co-Founder & Cso

Cyril Bauvais

Director, Head Of Bio-Imaging Lab

Nicolas Martin

Director, Head Of Business Development Eu

Marion Laguette

Director - Strategic Planning, Corporate Development And Operations

Nicolas Do Huu

Founder, Chief Technology Officer

Guillaume Bollot

Director Drug Discovery

Eleonora Echegaray

Marketing & Communications Director

Company overview

Headquarters	65, Rue de Prony, Paris, Île-de-France 75017, FR
Phone number	+33973584548
Websites	iktos.ai iktos.com
SIC	873
Keywords	Robotics, Automation, Artificial Intelligence, Deep Learning, Machine Learning, Cadd, Drug Design, MPO, Chemoinformatics, Lead Optimization, Qsar, Medicinal Chemistry, Molecular Modeling, De Novo Drug Design, Inverse-Qsar
Founded	2016
Employees	51-100
Socials

About iktos

We are a leader in artificial intelligence and robotic solutions applied to research in medicinal chemistry and new drug design. Iktos' proprietary and innovative generative AI solution enables the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology through the SaaS software platforms Makya™ for generative drug design and Spaya™ for retrosynthesis, and through strategic collaborations with pharma companies where Iktos mobilizes its unique platform and leading-edge capabilities to expedite small molecule drug discovery for the benefit of its partners. Iktos has also developed Iktos Robotics, a unique AI-driven synthesis automation platform that dramatically accelerates the Design-Make-Test-Analyze cycle in drug discovery and is developing its own pipeline of drug candidates targeting oncology and auto-immune and inflammatory diseases. In March 2023, Iktos completed a 15.5M€ Series A financing round co-led by M Ventures and Debiopharm Innovation with contribution by Omnes Capital. In July 2024, Iktos announced the acquisition of Synsight, thereby complementing its Chemistry AI platform with a groundbreaking biology platform for the discovery of new drugs targeting Protein-Protein Interactions (PPI) and RNA-Protein Interactions (RPI). In 2025, Iktos was awarded a €2.5M grant from the European Innovation Council (EIC) Accelerator, with potential follow-on funding of €5M, to advance its integrated AI and robotics platform.